Serving Size 1 capsule
Amount per serving		%DV
Cytidine 5-diphosphocholine	250 mg	†
† Daily Value not established
Other Ingredients: Magnesium stearate, Gelatin
Suggested Use: 1 capsule daily, or as directed by a health care professional.

Kaina$36.24

Sale$30.95

Jus sutaupote$5.29 (15%)

Kiek.

Pridėti į krepšelį Žiūrėti krepšelį Shipping Calculator

TiekimasUsually ships in 24 hours

PristatymasCan ship anywhere

Svoris6 oz

Overview

CDP-choline (Citicoline) — reversing nerve damage at the molecular level

CDP-choline (Citicoline) is a form of the B-vitamin choline. It is used by the body to make cell membranes and also to make the neurotransmitter acetylcholine.

CDP-choline began to be used in the 1960s as a treatment for brain injuries, and interest in it has grown with the realization that it offers a degree of protection against various kinds of damage to the nervous system (including the retina and optic nerve).

CDP-choline has been the focus of countless experiments using cell culture and lab animals, and many thousands of human volunteers and patients have participated in clinical studies of this compound. There is now considerable evidence that CDP-choline has neuro-protective and neuro-regenerative effects that can ameliorate the following conditions:

glaucoma-related damage to the eye
amblyopia (poor vision in one eye; “lazy eye”)
Alzheimer’s Disease
Parkinson’s Disease
age-related learning and memory disorders
traumatic brain injury
stroke
drug addiction.

The brain-bioavailability of CDP-choline is low, because the majority of the consumed dose is used outside of the brain. Fortunately the substance is not terribly expensive and so the low brain-bioavailability can be compensated for by using fairly large doses — 1000 mg/day, for example. The lack of toxicity of the supplement makes this possible without causing significant side effects.

Read CDP-Choline (Citicoline) Monograph

CDP-choline is a form of the B-vitamin choline. It is an intermediate in the synthesis of components of cell membranes and of the neurotransmitter acetylcholine. It also is a precursor of betaine, which is involved in gene regulation.

The biochemistry of CDP-choline has been studied since the 1950s and its clinical use began in the 1960s as a treatment for brain injuries.¹ Progress has been very slow, perhaps because the potential applications of the substance were patented and were then subjected to financial and legal game-playing by the patent owner and licensees. Development was further plagued by clinical studies that sometimes reached conflicting results. Even now there is not yet a consensus on optimum dosages for various conditions. Nevertheless, interest in this supplement remains high; and there is general agreement that it offers a degree of protection against various kinds of damage to the nervous system (including the retina and optic nerve).

The neuroprotective effects of CDP-choline may derive from its ability to increase the synthesis of phosphatidylcholines in injured nervous tissue.² Phosphatidylcholines are major components of cell membranes.

What we can’t tell you

In the U.S. and some other industrialized countries, government agencies like the U.S. Food and Drug Administration have adopted censorship as a method for intensifying their control over the supplement industry and its customers. Thus, FDA regulations prohibit us from telling you that any of our products are effective as medical treatments, even if they are, in fact, effective.

Accordingly, we will limit our discussion of CDP-choline to a brief summary of relevant research, and let you draw your own conclusions about what medical conditions it may be effective in treating.

CDP-choline has been the focus of countless experiments using cell culture and lab animals, and many thousands of human volunteers and patients have participated in clinical studies of this compound.³ There is now considerable evidence that CDP-choline has neuroprotective and neuro-regenerative effects that can ameliorate the following conditions:^3,⁴

glaucoma-related damage to the eye^15,⁷
amblyopia (poor vision in one eye; “lazy eye”)^14,⁷
Alzheimer’s Disease^6,⁷
Parkinson’s Disease^7,^8,⁹
age-related learning and memory disorders¹⁰
traumatic brain injury²
stroke⁵
drug addiction^11,^12,¹³

CDP-choline as a treatment for visual problems

Two kinds of vision problems have been shown to be improved by CDP-choline supplementation. Both are problems stemming from damaged nerves.

Glaucoma results from damage to nerve cells which transmit information from the retina into the brain. Treatment of glaucoma patients with oral CDP-choline (1600 mg/day for 60 days) resulted in “Improvement of retinal function (objectively evaluated by pattern electroretinogram recordings) and of neural conduction along visual pathways…”¹⁵

Amblyopia (a.k.a. “lazy eye”) is a visual disorder in which one eye has poor vision despite having no significant defect in the eye itself. It is thought to be caused by damage to the brain's visual centers or to the optic nerve. CDP-choline has been tested in children with amblyopia and found to improve visual acuity, contrast sensitivity, and strength of visual responses.¹⁶ When combined with patching, it leads to more stable benefits than those achieved with patching alone.¹⁴

CDP-choline for Alzheimer’s and Parkinson’s

When CDP-choline was administered to early-to-mid-stage Parkinson’s patients it led to significant improvement in symptoms. Advanced Parkinson’s patients appeared not to benefit from the treatment.^8,⁹

A number of clinical trials have demonstrated an ability of CDP-choline to reverse the cognitive symptoms of Alzheimer’s Disease. For example, in 1999 Spanish researchers reported that 1000 mg/day of CDP-choline “…Improves cognitive performance, cerebral blood perfusion and the brain bioelectrical activity pattern in AD patients.” The treatment was more effective in some types of Alzheimer’s Disease than in others.⁶

CDP-choline’s action against Alzheimer’s symptoms may be due in part to its ability to keep nerve cells alive under conditions that normally would cause them to self-destruct. Some of the damage done to the brain by Alzheimer’s Disease is thought to be due to the triggering of cell suicide (“apoptosis”) by the plaques of amyloid protein that are a hallmark of the disease. A study in 1999 implanted amyloid protein in various parts of rats’ brains. Those rats that were also treated with CDP-choline suffered less neurodegeneration and performed better in cognitive tests than rats that received no CDP-choline.¹⁷

Traumatic brain injury

The toll taken by traumatic brain injury is enormous — every year, approximately 1.4 million Americans sustain such an injury, of which 50,000 die, another 235,000 are hospitalized, and 80,000–90,000 people suffer permanent disability.²

At long last, a major clinical trial has been organized to find out whether CDP-choline’s benefits in stroke and dementia can be translated into a treatment for traumatic brain injury. The trial, called COBRIT, started in 2007 but is still recruiting participants (as of April 2010); it is scheduled to be completed in December 2010.²⁰ We eagerly await the results, which we anticipate will catapult CDP-choline into a first-line treatment for such injuries.

Stroke

CDP-choline as a treatment for stroke has received a considerable amount of research attention. The evidence suggests that if stroke patients are treated with 2000 mg of CDP-choline within the first 24 hours after having the stroke, their probability of complete recovery at 3 months will be increased by about 8%.⁵

Schizophrenia

In a recent collaboration between LifeLink and researchers at Georgetown University and the U.S. Department of Veterans Affairs, a new application for CDP-choline has been shown: treatment of schizophrenia. Researchers previously had suspected that at least some aspects of schizophrenia may be caused by a defect in a molecular channel in nerve cell membranes — specifically, a defect in the alpha7 nicotinic acetylcholine receptor located in this channel. That suspicion has now been confirmed by a 12-week-long clinical trial in which patients were given a combination of CDP-choline (supplied by LifeLink) and the drug galantamine; the trial showed that 5 out of 6 subjects receiving this treatment experienced a “reduction in Clinical Global Impressions severity scores and Positive and Negative Syndrome Scale total scores.”²²

Side effects

CDP-choline typically is without side effects. Rarely a few users experience digestive intolerance, gastrointestinal discomfort or restlessness.³

Bioavailability

When taken orally CDP-choline is converted in the intestine into cytidine and choline, both of which are efficiently absorbed into the bloodstream.²¹ These components are then transported throughout the body where they are utilized in various biosynthetic pathways.⁴ A small fraction of the cytidine and choline pass through the blood-brain barrier and are converted in the brain back into CDP-choline.⁴

The brain-bioavailability of CDP-choline is therefore low, since the majority of the consumed dose is used (or wasted) outside of the brain. Fortunately the substance is not prohibitively expensive and the low brain-bioavailability can be compensated for by using fairly large doses — 1000 mg/day, for example. The lack of toxicity of the supplement makes this possible without causing significant side effects.

Conclusion

Are CDP-choline supplements useful for the conditions and purposes mentioned above? We aren’t allowed to tell you, so you should take a look at some of the references cited here, and then decide for yourself.